The time between the sample on which PD-L1 and NGS were performed and the start date of immunotherapy is heterogeneous, some having had it just before the start of treatment, others having much older samples with intercurrent treatments, which may result in genomic and environmental tumor changes (> 6 months: 46 patients; > 12 months: 27 patients). The gene discussed is CD274; the disease is neoplasm.